Board of Directors
Bob holds the position of Executive Chairman at Couchbase and previously served as President and Chief Executive Officer at Couchbase from 2010 to 2017. Prior to Couchbase, Bob was chairman, CEO, and president of Transitive Corporation, the worldwide leader in cross-platform virtualization with over 20 million users, until it was acquired by IBM in 2008. Before Transitive, he was president and CEO of Tality Corporation, the worldwide leader in electronic design services, whose revenues and size grew to almost $200 million and had 1,500 worldwide employees.
Bob held several executive general management positions at Cadence Design Systems, Inc., an electronic design automation company, which he joined in 1985 as an early stage startup and helped to grow to more than $1.5 billion during his 13 years at the company. Bob also headed High Level Design Systems, a successful electronic design automation startup that was acquired by Cadence in 1996. Bob holds a bachelor’s degree in Electrical Engineering from University of Massachusetts Amherst and a master’s from Cornell University in Electrical Engineering.
CHIEF EXECUTIVE OFFICER
Tim is an experienced technology venture entrepreneur with an R&D background in both the physical and life sciences. Before joining Synthace he spent 7 years as Chief Operating Officer of CellCentric, a leading epigenetics drug discovery company. Prior to that he was Chief Technology Officer of Arrow Therapeutics and was co-founder and General Manager of DNA microarray tools company Oxford Gene Technology (Operations).
Before entering the commercial world Tim spent 13 years performing highly interdisciplinary research at the University of Oxford holding post-doctoral positions in three different departments (Biochemistry, Engineering and Materials). He has a D.Phil in Semiconductor Materials and an MBA from London Business School.
Tim is the Chairman of the UK BioIndustry Association’s Engineering Biology Advisory Committee and also a member of the Synthetic Biology Leadership Council co-chaired by The Rt Hon Lord Henley, Parliamentary Under Secretary of State at the Department for Business, Energy and Industrial Strategy.
Dr. Shiff joined Merck in 2014 as Senior Vice President and head of the CORE organization. CORE links together epidemiologists, health economists, access and reimbursement scientists, health services researchers and others involved in health policy research with the goal of leading global strategic value evidence generation and access strategy development to optimize reimbursement and patient outcomes across Merck’s portfolio. Prior to joining Merck, Dr. Shiff was the Global Vice President, Health Economics Research and Evidence Based Medicine at Teva, Inc. Prior to Teva, she spent seven years at Pfizer, including several years as Vice President in the areas of outcomes research, epidemiology, health economics, and access and pricing. She has also led the global risk management group and US HEOR group at Roche and spent four years at the U.S. Centers for Disease Control and Prevention (CDC). In 2016, Dr. Shiff was named one of the top 15 women in Biopharma by FiercePharma. Susan received her Ph.D. degree from UCLA, and an MBA degree from Cornell University. Dr. Shiff currently serves on the Institute for Clinical and Economic Review (ICER), Advisory Board and Methods Sub-Committee; Health Technology Assessment International (HTAi), Policy Advisory Board; the Innovation and Value Initiative (IVI), Panel of Health Advisors, the Academy of Managed Care Pharmacy (AMCP) Foundation Board, and the New Jersey Symphony Orchestra, Board of Trustees, Education, and Development Committees. Dr. Shiff is also a Non-Executive Director of Synthace Ltd and a voting member of the Merck Global Health Innovation Fund, LLC, Innovation Venture Board.
Isabel Fox is the Head of Venture Capital at White Cloud, investing predominantly in healthcare and education start-ups in Europe, Asia and Australasia. She started out in finance, followed by financial PR (tech IPOs) before founding two corporate/tech PR firms. She was also a part of the founding team of two software start-ups and an active investor in the UK and US.
Izzy is an advisor and angel investor in several start-ups including Adbrain, Jumio, BitPay, Get Around, Violin Memory, Tray.io, Cloud House, GetCrane and more. As an INN graduate, her passion is health and wellbeing and shaping the future of healthcare.
Joško joined Sofinnova in 2010 as Partner of the Sofinnova Green Seed Fund dedicated to seed activities in renewable chemistry and bio-energy. Prior to joining Sofinnova, he spent eight years in venture capital with iNovia Capital and its fund MSBi Capital in Montreal, Canada. Joško was responsible for cleantech investments at the fund and focused on seed and early-stage investments in cleantech and information technology.
Prior to his venture capital career, he created an internet start-up and a software company. After completing his PhD studies Joško developed real-time ocean forecasting systems still used at Environment Canada for coastal ocean management. Joško holds a BSc. in physics from the University of Zagreb, a PhD in physical oceanography from Dalhousie University and an MBA in finance and marketing from McGill University.
Patrick Zhang is an investor at Horizons Ventures, where he primarily covers biotechnology and healthcare investments, and manages related portfolio companies for Horizons. He was trained as a chemical engineer and worked in a variety of organizations across industries including power utilities, financial services and investment management. Prior to Horizons, Patrick was an investment banker with Morgan Stanley providing financial advisory services on capital raising and cross-border M&A to his clients. Mr. Zhang received his BS degree in Chemical Engineering from UCLA and MBA from Columbia Business School.
mICHAEL (SID) sADOWSKI
HEAD OF BIOINFORMATICS
Dr Sadowski (usually called Sid) is a passionate and enthusiastic computational biologist of some 15 years’ standing with a background in protein sequence, structure and function analysis. His life in bioinformatics started at Leeds with Dave Westhead and J. Howard Parish, followed by postdocs at UCL and NIMR with David Jones and Willie Taylor.
CHIEF COMMERCIAL OFFICER
Mark has a proven track record of growing numerous companies into hundred million dollar businesses. Mark developed his flair for execution through his experience of working for blue chip companies and serving as a non-executive director on a number of boards.
Prior to joining Synthace, he held senior positions at a number of top firms including, Siemens, Logica, Midland Montagu, Oracle, Micromuse, Axiom and Sage. He was also a founding partner of a leading sales acceleration consultancy. As well as being a trained accountant, Mark is a fully-qualified member of Chartered Institute of Marketing (MCIM) and holds a first class degree in Industrial Management.
CHIEF FINANCIAL OFFICER
Jonathan joined Synthace in March 2018. He's responsible for financial and commercial support. A twenty five year veteran of the B2B software and services industry, Jonathan's career started as an accountant at PWC and then EDS. He subsequently held finance roles in NASDAQ listed companies. Prior to Synthace, he was formerly COO/CFO of Rouse & Co International LLP, a boutique legal services IP group active in emerging markets, and acted as an advisor on several private equity investments in the healthcare and cleantech sectors.
Jonathan is a UK ACA, MCT and MA (Hons) Cantab,.
CHIEF SCIENTIFIC OFFICER
Markus co-founded Synthace after working as a Research Associate in Synthetic Biology at University College London where he developed novel biosynthesis methods using pathway engineering. Prior to UCL, he was a Biotransformation Scientist at Novacta Biosystems working as part of the industrial biotechnology group that conducted more than 90 contract research projects for over 20 clients. Markus has a PhD in Plant Biochemistry from Durham.
Join our interdisciplinary team of biologists, computer scientists, biochemical engineers, and statisticians as we work together to expand the boundaries of science and technology